 Connection
Bradley Corr to Aged, 80 and over
This is a "connection" page, showing publications Bradley Corr has written about Aged, 80 and over.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.561 |
|
|
|
-
Corr BR, Haggerty A, Gysler SM, Taylor S, Behbakht K, Alldredge J, Lefkowits C, Brubaker LW, Bouts C, Babayan LM, Martin LP, Costello J, Bitler BG, Hu J, Guntupalli SR. A phase II, randomized, double-blind study of the use of rucaparib vs. placebo maintenance therapy in metastatic and recurrent endometrial cancer. Gynecol Oncol. 2025 Sep; 200:58-67.
Score: 0.103
-
Corr BR, Moroney M, Sheeder J, Eckhardt SG, Sawyer B, Behbakht K, Diamond JR. Survival and clinical outcomes of patients with ovarian cancer who were treated on phase 1 clinical trials. Cancer. 2020 10 01; 126(19):4289-4293.
Score: 0.073
-
Corr BR, Mantia-Smaldone G, Cantor J, Livolsi VA, Furth E, Chu CS. Metastatic cholangiocarcinoma to the ovary: a case series. Int J Gynecol Pathol. 2013 Nov; 32(6):562-5.
Score: 0.046
-
Robin TP, Hu J, Jones BL, Patton T, Diamond JR, Behbakht K, Lefkowits C, Corr BR, Fisher CM. Phase I trial of stereotactic body radiation therapy (SBRT) for limited site locoregional recurrences of ovarian cancer. Gynecol Oncol. 2025 Sep; 200:175-179.
Score: 0.026
-
Lee SS, Secord AA, Friedman S, Hade EM, Smitherman C, Bisht N, Borden L, Jackson AL, Backes F, Thaker P, Arend R, Wright JD, Corr B, Ko E, Konecny G, Podwika S, Bae-Jump V, Hacker KE, Pothuri B. Molecular characteristics by race and ethnicity of patients with high tumor mutational burden, high microsatellite instability, and mismatch repair deficiency: Real-world data from the multi-institutional Endometrial cancer Molecularly Targeted Therapy Consortium (ECMT2). Gynecol Oncol. 2025 Aug; 199:152-158.
Score: 0.026
-
Liu JF, Colombo N, Oza AM, Frenel JS, Corr BR, Rubinstein MM, Nevadunsky NS, Lheureux S, Gaba L, Gonz?lez Cortijo L, Salutari V, You B, Chiang S, O'Connor MJ, Oplustil O'Connor L, Meulendijks D, Khatun M, Ghiorghiu D, Oaknin A. ADAGIO: A Phase IIb, Open-Label, Single-Arm, Multicenter Study Assessing the Efficacy and Safety of Adavosertib (AZD1775) as Treatment for Recurrent or Persistent Uterine Serous Carcinoma. J Clin Oncol. 2025 Sep 10; 43(26):2897-2907.
Score: 0.025
-
Secord AA, Bae-Jump V, Backes F, Thaker P, Gehrig PA, Previs RA, Borden L, Thomas SM, Jackson A, Konecny GE, Duska LR, Arend R, Wright J, Corr B, Maxwell GL, Cosgrove CM, Mullen MM, Washington C, Herzog TJ, Cohen J, Hou J, Gaillard S, Fader AN, Berchuck A, Pothuri B. Genomic alterations, molecularly targeted therapy, and survival: a real-world Endometrial Cancer Molecularly Targeted Therapy Consortium cohort study. Int J Gynecol Cancer. 2025 May; 35(5):101758.
Score: 0.025
-
Alqaisi HA, Cohn DE, Chern JY, Duska LR, Jewell A, Corr BR, Winer IS, Girda E, Crispens MA, Dhani NC, Madariaga A, Grant RC, Malaguti M, Lee C, Bowering V, Wong H, Poothullil A, Speers V, Wang L, Bedard PL, Brady JC, Nixon AB, Chen L, O'Connor C, Zamboni W, McKee T, Moscow JA, Oza AM, Lheureux S. Randomized Phase II Study of Bevacizumab with Weekly Anetumab Ravtansine or Weekly Paclitaxel in Platinum-Resistant/Refractory High-Grade Ovarian Cancer (NCI Trial). Clin Cancer Res. 2025 Mar 17; 31(6):993-1001.
Score: 0.025
-
Haight PJ, Sanchez M, Thomas SM, Smitherman C, Cosgrove C, Bae-Jump V, Crafton S, Hacker K, Ko E, Krivak T, Lara O, Moore K, Mullen MM, Pothuri B, Thaker PH, Washington C, Arend R, Corr B, Duska L, Jackson A, Konecny GE, Wright J, Secord A, Backes F. Platinum-free interval and response to platinum retreatment or lenvatinib/pembrolizumab in patients with recurrent endometrial cancer: A real-world endometrial cancer molecularly targeted therapy consortium cohort study. Gynecol Oncol. 2025 Mar; 194:98-104.
Score: 0.025
-
Alvarez Secord A, Lewin SN, Murphy CG, Cecere SC, Barqu?n A, G?lvez-Montosa F, Mathews CA, Konecny GE, Ray-Coquard I, Oaknin A, Rubio P?rez MJ, Bonaventura A, Diver EJ, Ayuk SM, Wang Y, Corr BR, Salutari V. The efficacy and safety of mirvetuximab soravtansine in FRa-positive, third-line and later, recurrent platinum-sensitive ovarian cancer: the single-arm phase II PICCOLO trial. Ann Oncol. 2025 Mar; 36(3):321-330.
Score: 0.025
-
Santin AD, Corr BR, Spira A, Willmott L, Butrynski J, Tse KY, Patel J, Mekan S, Wu T, Lin KW, Kuo P, Dumbrava EE. Efficacy and Safety of Sacituzumab Govitecan in Patients With Advanced Solid Tumors (TROPiCS-03): Analysis in Patients With Advanced Endometrial Cancer. J Clin Oncol. 2024 Oct 10; 42(29):3421-3429.
Score: 0.024
-
Gonz?lez-Mart?n A, Chung HC, Saada-Bouzid E, Yanez E, Senellart H, Cassier PA, Basu B, Corr BR, Girda E, Dutcus C, Okpara CE, Ghori R, Jin F, Groisberg R, Lwin Z. Lenvatinib plus pembrolizumab for patients with previously treated advanced ovarian cancer: Results from the phase 2 multicohort LEAP-005 study. Gynecol Oncol. 2024 07; 186:182-190.
Score: 0.024
-
Davies KD, Smith LP, Guimaraes-Young A, Corr BR, Fisher CM, Guntupalli SR, Berning AA, Post MD, Pino D, Aisner DL, Wolsky RJ. Prospective Clinical Prognostication of Endometrial Carcinomas Based on Next-Generation Sequencing and Immunohistochemistry-Real-World Implementation and Results at a Tertiary Care Center. Int J Gynecol Pathol. 2024 Jul 01; 43(4):335-348.
Score: 0.023
-
Guntupalli SR, Brennecke A, Behbakht K, Tayebnejad A, Breed CA, Babayan LM, Cheng G, Ramzan AA, Wheeler LJ, Corr BR, Lefkowits C, Sheeder J, Matsuo K, Flink D. Safety and Efficacy of Apixaban vs Enoxaparin for Preventing Postoperative Venous Thromboembolism in Women Undergoing Surgery for Gynecologic Malignant Neoplasm: A Randomized Clinical Trial. JAMA Netw Open. 2020 06 01; 3(6):e207410.
Score: 0.018
-
Amini A, Robin TP, Rusthoven CG, Schefter TE, Akhavan D, Chen YJ, Glaser SM, Corr BR, Ashing KT, Fisher CM. Disparities Predict for Higher Rates of Cut-through Hysterectomies in Locally Advanced Cervical Cancer. Am J Clin Oncol. 2019 01; 42(1):21-26.
Score: 0.016
-
Amini A, Robin TP, Stumpf PK, Rusthoven C, Schefter TE, Shinde A, Chen YJ, Glaser SM, Corr BR, Fisher CM. Rising Rates of Upfront Surgery in Early Locally Advanced Cervical Cancer: What Factors Predict for This Treatment Paradigm? Int J Gynecol Cancer. 2018 10; 28(8):1560-1568.
Score: 0.016
-
Ramzan AA, Behbakht K, Corr BR, Sheeder J, Guntupalli SR. Minority Race Predicts Treatment by Non-gynecologic Oncologists in Women with Gynecologic Cancer. Ann Surg Oncol. 2018 Nov; 25(12):3685-3691.
Score: 0.016
-
Doo DW, Guntupalli SR, Corr BR, Sheeder J, Davidson SA, Behbakht K, Jarrett MJ, Guy MS. Comparative Surgical Outcomes for Endometrial Cancer Patients 65 Years Old or Older Staged With Robotics or Laparotomy. Ann Surg Oncol. 2015 Oct; 22(11):3687-94.
Score: 0.012
-
Traynor BJ, Alexander M, Corr B, Frost E, Hardiman O. Effect of a multidisciplinary amyotrophic lateral sclerosis (ALS) clinic on ALS survival: a population based study, 1996-2000. J Neurol Neurosurg Psychiatry. 2003 Sep; 74(9):1258-61.
Score: 0.006
-
Traynor BJ, Codd MB, Corr B, Forde C, Frost E, Hardiman OM. Clinical features of amyotrophic lateral sclerosis according to the El Escorial and Airlie House diagnostic criteria: A population-based study. Arch Neurol. 2000 Aug; 57(8):1171-6.
Score: 0.005
-
Traynor BJ, Codd MB, Corr B, Forde C, Frost E, Hardiman O. Amyotrophic lateral sclerosis mimic syndromes: a population-based study. Arch Neurol. 2000 Jan; 57(1):109-13.
Score: 0.004
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|